Dr Tykodi discusses the importance of clinical risk factors in the treatment of mRCC,3 when and how to treat mRCC with high-dose interleukin-2,1,3 recent developments in checkpoint inhibitor therapy,4 and how these might affect the role of high-dose interleukin-2 in the treatment of favorable-risk mRCC patients.51/2 Next Interview
Dr Curti discusses recent analyses of data from the PROCLAIMSM database, with a focus on high-dose interleukin-2 therapy,2,5 the safety of high-dose interleukin-2 in favorable-risk mRCC patients,1 how these findings might affect the treatment paradigm for mRCC and potential future research to improve patient outcomes and survival.2/2 Leave Feedback
Overview & Learning Objectives
High-dose interleukin-2 therapy is one of the few treatments for adults with metastatic renal cell cancer (mRCC) that can produce complete responses that are often durable for decades without further therapy.1-3 We interviewed leading experts about the current status of high-dose interleukin-2 therapy,1 when and how it should be considered,4 recent developments in checkpoint inhibitor therapy to treat mRCC,5,6 the findings from a recent analysis of the PROCLAIMSM registry into the efficacy of high-dose interleukin-2 therapy in favorable-risk mRCC patients,2,7 and the impact of these developments on the overall treatment paradigm.
After watching this activity, you should be able to:
- Understand the importance of clinical risk factors in the treatment and management of mRCC and be aware of the current NCCN recommendations.
- Appreciate the clinical benefits and safety profile, including risks, of high-dose interleukin-2 therapy and how these may guide treatment decisions dependent on clinical risk factors.
- Demonstrate an awareness of the results of the CheckMate 214 study, showing differing survival and clinical response outcomes in patients with mRCC receiving checkpoint inhibitor therapy dependent on disease risk category.
- Understand the latest results from the PROCLAIMSM database, showing consistent survival benefits with high-dose interleukin-2 therapy across favorable, intermediate and poor-risk mRCC patients.
- Appreciate how these recent findings might alter the treatment paradigm for mRCC.
Clinigen, Inc. PROLEUKIN® (aldesleukin) prescribing information.
Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC). You are encouraged to report negative side effects of prescription drugs to the FDA.
- Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
- Dutcher JP, et al. J Immunother Cancer 2014;2:26.
- Clark JI, et al. Clin Genitourin Cancer 2017;15:31-41 e4.
- Clinigen, Inc. PROLEUKIN® (aldesleukin) prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf
- National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
- Motzer RJ, et al. N Engl J Med 2018;378:1277-90.
- Buchbinder EI, et al. J Immunother Cancer 2019;7:49.
- Fishman M, et al. J Immunother Cancer 2019;7:84.